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Stiffnessfrom synthetic or natural materials have many applications in tissue engineering
and medicine, and multiple material properties need to be optimized for speciﬁc applications. Recent studies
have emphasized the importance of the scaffolds' mechanical properties to support speciﬁc cellular
responses in addition to considerations of biochemical interactions, material transport, immunogenicity, and
other factors that determine biocompatibility. Fibrin gels formed from puriﬁed ﬁbrinogen and thrombin, the
ﬁnal two reactants in the blood coagulation cascade, have long been shown to be effective in wound healing
and supporting the growth of cells in vitro and in vivo. Fibrin, even without additional growth factors or
other components has potential for use in neuronal wound healing in part because of its mechanical
compliance that supports the growth of neurons without activation of glial proliferation. This review
summarizes issues related to the use of ﬁbrin gels in neuronal cell contexts, with an emphasis on issues of
immunogenicity, and considers the potential advantages and disadvantages of ﬁbrin prepared from non-
mammalian sources.
© 2009 Elsevier B.V. All rights reserved.1. IntroductionThe elastic properties of tissues and biomaterials designed to
promote wound healing or regeneration in speciﬁc settings has until
recently not been considered as an essential design feature. Most
studies have addressed the biochemical and structural properties of
scaffolds and extracellular matrices that dictate the molecular
speciﬁcity of cell adhesions and the transport of soluble factors into
and away from the site of repair. A series of recent studies have
rejuvenated interest in studying how tissue and biomaterial stiffness
inﬂuences the structure and function of cells by showing that matrix
stiffness, under conditions where other factors are held constant, has
a large effect on the rate of cell proliferation, speciﬁc programs of
gene expression, cell motility, and the developmental fate of stem
cells [1–3]. In some cases, matrix stiffness can override chemical
stimuli, as illustrated by the lack of response to osteogenic growth
factors when mesenchymal stem cells are plated on soft (b1000 Pa)
surfaces [4], and in other cases the nature of the adhesive ligandd Engineering, University of
, USA.
anmey).
ll rights reserved.works in concert with substrate mechanics to direct speciﬁc
processes such as the interplay between the type of integrin ligand
and the substrate stiffness on the formation of actin stress ﬁbers or
the modulation of motility [5–7].
Not all cells respond similarly to matrix stiffness, and some cell
types such as neutrophils seem not to respond to stiffness differences
in the range that strongly affect other cell types [5]. One setting in
which the elasticity of the substrate appears to have a highly speciﬁc
effect is in the central nervous system. The brain is among the softest
human tissues, with a time-dependent shear storage modulus (or,
depending on the type of rheologic measurement, Young's modulus)
that varies from N 1000 Pa at millisecond time scales appropriate for
modeling effects of impact, to a relatively steady level near 200 Pa at
time scales on the order of seconds [8,9]. At sites of injury, where glial
scarring occurs, the local stiffness can be palpably higher, but is not yet
quantitatively determined, and the stiffness difference at the interface
of the glial scar can act as a physical as well as a chemical barrier to
neurite extension and neuronal repair in severe injuries [9,10].
The possibility that soft materials might be particularly useful in
restoration of diseased CNS tissue is related to the ﬁnding that two
main cell types of the CNS, neurons and astrocytes, respond in very
different ways to matrix stiffness [10], and that gels of low elastic
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cells [9]. Spinal cord and cortical brain neurons extend neurites and
form branches more avidly on soft materials, and are the only cell
type thus far documented to be inhibited from extending as the
matrix becomes stiffer than the stiffness of a normal brain
(b1000 Pa) [9,11–15]. In contrast, astrocytes, like numerous other
cell types, develop stress ﬁbers, increase spread area, and become
activated on stiff surfaces [10]. This article will focus on evidence of
the effects of manipulating substrate stiffness that may have utility in
the central nervous system and other injury settings and on the
speciﬁc properties of matrices derived from non-mammalian clotting
factors such as salmon ﬁbrinogen and thrombin that have potential
advantages or complementary properties compared to synthetic or
human-derived materials.
1.1. Advantages of ﬁbrin from non-mammalian sources
Fibrin has a long and extensive record of use in wound healing
including treatment of trauma to the brain and spinal cord [16,17].
Fibrin is the normal scaffold that ﬁrst forms at sites where trauma to
cells initiates the cascade of reactions leading to blood clotting.
Puriﬁcation of the two ﬁnal reactants, ﬁbrinogen and thrombin, and
administration in controlled amounts at deﬁned locations has many
clinical applications [18]. The ﬁbrin scaffold can be supplementedwith
growth factors and other agents for speciﬁc settings and is simple to
administer, with a straightforward injection into the affected region
[19]. The reaction occurs at physiological temperature and pH, and
both the rates of gelation and the mechanical properties of the
polymerized gel can be controlled easily by adjusting the injectionmix
[20,21].
Limitations of the use of ﬁbrin in CNS or other injuries include the
fact that ﬁbrin is designed to degrade at a rate that depends on the
production of plasmin and other proteases generated at the injured
site, and in some settings such as neural regeneration, ﬁbrin
degradation proceeds too rapidly to allow neurite inﬁltration without
the use of protease inhibitors that can have known or unanticipated
negative effects. Cells of the CNS, including neurons, astrocytes, and
microglia have receptors for thrombin, ﬁbrinogen or ﬁbrin that also
have potentially negative effects on neural wound healing. Human
ﬁbrin is also optimized to polymerize at slightly below 37 °C, and fails
to clot at lowered temperatures that are required in some surgical
settings, including CNS trauma. Additional concerns involve the
potential for infectious agents introduced by using proteins derived
from pooled human or other mammalian sources. Some of these
limitations can be overcome by non-mammalian coagulation proteins,
such as have been puriﬁed from salmon blood [22–26]. Worldwide
production of farmed salmon now exceeds a million metric tons
annually. Therefore, millions of liters of blood with consistent quality
are available from animals where genetics, nutrition, and environ-
ment are controlled or closely monitored.
Proteins derived from salmon or other non-mammalian tissues are
likely to be safe from mammalian infectious agents due to the wide
evolutionary distance between ﬁsh and humans. The low body
temperature of cold water ﬁsh serves as another barrier to cross-
species survival of bacteria or viruses. Prion infection is also most
probable in species with similar prion proteins. Although salmon do
have a normal isoform of prion protein, its structure is quite different
from the mammalian protein [27] and therefore presents little risk.
Also, there is no evidence of prion disease in ﬁsh, and even if farmed
ﬁsh ingest mammalian prions, the infectivity is quickly cleared [28].
Prion contamination is a special concern in ﬁbrinogen products,
because mammalian ﬁbrinogen can selectively bind the infective part
of the prion protein [29].
Salmon ﬁbrinogen and thrombin are sufﬁciently similar to human
ﬁbrinogen and thrombin to be interchangeable in terms of ﬁbrin
polymerization, but they differ subtly from those of the humanproteins both in amino acid sequence and the nature of glycosylation
[23,24,30]. For example, whereas salmon thrombin activates human
platelets (a cell type absent in ﬁsh) the time course of platelet
aggregation in vitro is slightly different, suggesting that salmon
thrombin activates the major human platelet receptor, but might not
fully activate other cellular targets [23]. The A-alpha chain of salmon
ﬁbrinogen has signiﬁcant lower molecular weight compared to
human A-alpha, and the gamma chain of zebraﬁsh ﬁbrinogen, the
closest species to salmon that has been sequenced, lacks homology in
a region of human ﬁbrinogen that activates microglia [31] and is
thought to contribute to inﬂammation in the CNS.
Differences between salmon andmammalian ﬁbrin are apparent in
several studies in which these scaffolds have been compared in cell
culture and animal models. Mammalian neurite outgrowth in vitro is
signiﬁcantly less in human or bovine ﬁbrin compared to salmon ﬁbrin
in three dimensional ﬁbrin gels [33]. Human ﬁbrinogen inhibits
neurite outgrowth while salmon ﬁbrin does not, possibly via
outgrowth by triggering an inhibitory signal transduction pathway
in neurons [34]. Human ﬁbrinogen polymerizes slowly below 37 °C
but salmon ﬁbrinogen clots normally down to 0 °C [30]. Since
outcomes can be improved by hypothermia after traumatic brain
injury [35] and possibly spinal cord injury [36], salmon ﬁbrin could be
effective for the coagulopathy seen at low body temperature.
1.2. Issues of immune response to foreign proteins and
biomaterial scaffolds
The same structural differences between salmon and mammalian
ﬁbrinogen and thrombin that in some context confers possible
advantages to use of non-mammalian ﬁbrin is potentially countered
by the presumed higher antigenicity of salmon proteins in a
mammalian host. The inﬂammatory response to synthetic and natural
tissue adhesives is variable, depending primarily on the contact of
tissue ﬂuids around the biomaterial and the access of host blood cells.
In general, host reactions following administration of biomaterials
include stages of blood-material interaction, provisional matrix
formation, acute inﬂammation, chronic inﬂammation, granulation
tissue development, foreign body reaction, and ﬁbrosis (ﬁbrous
capsule) development [37]. In the cascade of these events the role
of the immune system is signiﬁcant, but immune system activation
largely depends on the immunogenicity of tissue adhesives.
Synthetic tissue adhesives, as most widely used and continuously
developed, are relatively inert for the host immune system. For
example, if administered intravascularly to the rats, N-butyl-2-
cyanoacrylate induces only mild eosinophilic inﬂammation during
the ﬁrst day and after 7 days the tissue reaction is minimal [38].
However, small particles of cyanoacrylates can modulate immune
response to external antigens as demonstrated by Simeonova et al.
[39]. Currently it is believed that the adjuvant effect of synthetic
materials in stimulating dendritic cells and the adaptive immune
response to co-expressed (self)antigens may be more important than
was previously thought [40]. In addition, systemic inﬂammatory
reactions and septic complications can develop, but the conditions
that are needed for their development are not well known. Some of
these rare reactions can be life threatening due to fulminant
inﬂammatory reactions [41]. Delayed and recurrent chronic inﬂam-
matory and granulomatous reactions could be seen in response to
some synthetic gels [42]. However, polyethylene glycol based
biodegradable hydrogels used as tissue sealants do not appear to
induce immediate humoral or cellular immune reactions [43,44].
Thus in general, synthetic tissue adhesives do not necessarily
strongly initiate cross-talk with hosts' tissues and cells due to their
relatively passive role in tissue repair. However, the immune
reactions largely depend on the chemistry and physics of synthetic
biomaterials surfaces which contact the host tissue. Biomaterials'
surface characteristics have a signiﬁcant impact on antigen
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such as adhesion, apoptosis and cytokine secretion. These cells
continuously sense and internalize their surroundings by pattern
recognizing receptors orchestrating the immune system and inﬂam-
matory reactions towards the target tissue. As an example, alginate,
which is composed of alternating mannuronic and guluronic acid
residues has been shown to induce inﬂammatory response depend-
ing on the amount of mannuronic acid residues in the preparation
[45]. Thus by controlling the alginate composition it is possible to
modulate inﬂammatory reactions induced by sealants containing
alginate. Synthetic materials like polyglycolic acid are also able to
enhance immune response [40]. Unfortunately, thus far the interac-
tions between synthetic tissue adhesives and the immune system are
only superﬁcially studied in spite of the fact that specially designed
materials could stimulate the immune system to improve tissue
healing [46].
Native tissue adhesives represent natural bio-compounds of the
host to mimic the physiological situation and therefore their
interaction with cellular and humoral factors of the immune system
is more immediate. Here the immune system gets stronger direct
signals for its activation. The extent of activation depends on genetic
differences between donor (from where biomaterial is prepared) and
host tissues. Tissue sealants prepared from the individual's tissues to
be treated (autologous adhesives) are not immunogenic if their
composition is not physically or chemically altered i.e. there are no
neo-antigens recognized by the immune system as non-self. In a study
by van Nooten et al. [47] a 2-component glue with sufﬁcient elasticity
and tensile strength was made by mixing canine autologous plasma
concentrate with 7.5% glutaraldehyde and applied to dogs. As a result,
only mild inﬂammation with few lymphocytes and plasma cells
around the glue was formed. The absence of CD4+ T lymphocytes in
the inﬁltration was taken as evidence for the absence of antigen
presentation in the tissue treated with glue [47]. Protein preparations
from other individuals of the same species can acquire immunogeni-
city (for example due to blood group antigens contamination)
whereas xenogenic biomaterials from tissues of other species are
always immunogenic. The combination of allogenous and hetero-
logous proteins in ﬁbrinogen-coated collagen patches seems to
diminish immunological reactions against the patches' components
[48], but comprehensive immunological studies on these tissue
adhesives are still not available.
The use of recombinant human coagulation proteins, instead of
those prepared from blood with a possibility of contamination with
infectious agents, seems to offer a treatment device that has no
problems. However, an expectation that human recombinant protein
preparations would be non-immunogenic in patients capable of
synthesizing these proteins by themselves, is somewhat premature, if
we take into account the possibility that these preparations may
include trace amounts of ingredients originating from the expression
systems used for their preparation. Also incomplete or abnormal
post-translational modiﬁcation or other, even minimal changes in the
composition can render these preparations immunogenic [49]. Still,
recombinant human thrombin is less immunogenic for clinical use
than heterologous thrombin as has also been demonstrated by the
comparative clinical analysis of Weaver et al. [50]. In this study no
patients who underwent either a peripheral arterial bypass or
arteriovenous graft procedure and received recombinant human
thrombin seroconverted or had an increase in anti-thrombin anti-
body titer. In another study, the development of non-neutralized
antibodies to recombinant human thrombin was detected in 3 out of
198 patients [32].
The most commonly used native tissue sealants are thrombin- and
ﬁbrinogen-based. Thrombin-based products are often produced from
bovine plasma and ﬁbrinogen-based hemostatic agents derived from
human plasma [51]. Accordingly, the most serious immunological
problems could arise if bovine thrombin based ﬁbrin glue is used.Although tissue glues of such types have been safely and effectively
used for many years in thousands of patients, a number of
immunological complications have been reported. In most cases,
these complications are related to the development of immune
reactions against bovine thrombin preparations. Even a single
administration of bovine thrombin can mount a signiﬁcant immune
response, as has been shown by the development of autoantibodies
characteristic for the systemic autoimmunity in non-autoimmune-
prone mice [52]. If the patient has a propensity to develop such
antibodies or has pre-existing autoantibodies to thrombin, the
administration of bovine thrombin containing glue could induce or
potentiate immune reactions against autologous thrombin. In such
cases serious clinical consequences from the antithrombin autoanti-
bodies may appear. It is possible that these autoantibodies cause
either thrombosis [53] or hemorrhage [54]. The pathological outcome
of antithrombin antibodies likely depends on the antigenic epitope to
which they react. According to recent studies, thrombin autoantibo-
dies can be found in up to 40.9% of patients with systemic lupus
erythematosus and antiphospholipid syndrome [55]. Somewhat lower
frequencies have been reported earlier [56], however thrombin may
share common epitopes with prothrombin and beta2-glycoprotein I,
well known autoantigens in antiphospholipid syndrome [57]. Simi-
larly, antibodies to other bovine ﬁbrin glue components like factor Va
could arise [53], leading to the development of autoantibodies against
human factor Va which would impair the systemic coagulation with
serious clinical complications similar to those seen in cases of
spontaneously developed autoantibodies [58].
Administration of bovine ﬁbrin glue can also induce immediate
reactions in the form of Immunoglobulin E (IgE)-mediated anaphy-
laxis against thrombin [59,60]. If aprotinin of bovine origin is used in
ﬁbrin sealant to prevent lysis of the clot, anaphylactic reactions can
develop [61,62]. A speciﬁc immune response induced by local
aprotinin administration does not differ from that seen in intravenous
exposure [61].
The development of immune reactions to bovine ﬁbrin glue and
other glue materials of bovine origin is mostly due to the presence of
xenogenic carbohydrates such as Galα1-3Gal in bovine products [63].
These carbohydrates, not present in human ﬁbrinogen or thrombin,
are strong stimulators of immune response among humans. In bovine
thrombin preparations the source of Galα1-3Gal may not be thrombin
itself but rather this xenoantigen can be expressed on contaminating
proteins. Whatever the cause, 90% of humans exposed to a bovine
thrombin preparation develop IgG antibodies against one or more of
the proteins in the preparation [53].
In contrast to tissue sealants containing constituents of bovine
origin, coagulation proteins of salmon used for ﬁbrin glue develop-
ment do not express highly antigenic carbohydrate Galα1-3Gal.
However IgE and IgG antibodies can be developed to ﬁsh proteins,
probably induced by proteins rather than by carbohydrate residues.
Among ﬁsh proteins with potency to activate IgE (i.e. immediate
allergen) reactions, parvalbumin, a muscle protein, holds a special
position since parvalbumins from ﬁsh are considered to be the major
or sole allergens for 95% of the patients suffering from IgE-mediated
ﬁsh allergy [64]. So far parvalbumins of about 30 ﬁsh species have
been characterized [65] including salmon allergen Sal s1 [66,67].
Parvalbumins of different ﬁsh species show considerable cross-
reactivity and therefore are dangerous for individuals with known
ﬁsh allergy that account for about 0.1–0.3% of the general population
[65]. This salmonproteinwas also demonstrated to be antigenic by the
use of salmon antibodies in IgG ELISA and immunoelectrophoretic
methods [66]. However, since salmon thrombin and ﬁbrinogen are
prepared from salmon blood the possibility that the allergen Sal s1
derived from the ﬁsh muscle would contaminate salmon ﬁbrin glue
should be minimal.
Some reactions to ﬁsh proteins may also develop through cross-
reactions. Thus, pre-existing autoantibodies can react with ﬁsh
Fig. 1. Development of antibodies to salmon, but not endogenous, proteins after
administration of salmon ﬁbrin. Antibodies to salmon ﬁbrinogen (A) or thrombin (B)
were measured in rabbit plasma samples taken at various times before and after
intraperitoneal administration of salmon ﬁbrin on days 2 and 32. Open symbols are data
for samples from control animals treated with saline and solid symbols are from animals
treatedwith salmon ﬁbrin. (C) Comparison of antibody titres on day 42 for rabbits treated
with salmon ﬁbrin on days 2 and 32 reacting against salmon or rabbit ﬁbrinogen or
thrombin. Controls are for ELISA assays done on the same strips using plasma from control
animals treated with 0.9% saline in place of salmon ﬁbrin. (D) Thrombin times performed
on the same samples as used for antibody analyses. Adapted from [30].
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studies [23,24]. In these studies, as well as a later one by Laidmäe et al.
[30], no assays of immune response showed any unusual antigenicityFig. 2. Cultures of dissociated embryonic mouse brain cortices at 1 week in salmon ﬁbrin gels
75 Pa with decreasing concentration. Neurons are labeled for betaIII-tubulin (red) and astroof the salmon ﬁbrin sealant (Fig. 1). Humoral immune response to
salmon thrombin and ﬁbrinogen was studied after intraperitoneal
administration of salmon ﬁbrin glue to rabbits and rats. Using an
enzyme-linked immunosorbent assay and salmon thrombin and
ﬁbrinogen as antigens, only a mild increase of IgG binding to antigens
was demonstrated 1–3 weeks after the ﬁrst ﬁbrin glue administration.
As expected, after a second dose of salmon ﬁbrin glue, antibodies
levels were higher (Fig. 1A, B). In no case was an increase in clotting
times observed, demonstrating that the antibodies developed did not
affect the normal coagulation process (Fig. 1D). Notably, when rabbit
blood samples were tested with puriﬁed rabbit ﬁbrinogen and
thrombin, no antibodies were detected showing that autoantibodies
to host proteins have not been developed (Fig. 1C). These results were
further conﬁrmed in immunoblot studies on 23 control and 23
experimental rats where low intensity antibody reactions to other
polypeptides in thrombin and ﬁbrinogen preparations were found
[30]. As also demonstrated by other authors in association with
human proteins [68], salmon ﬁbrinogen is more immunogenic than
salmon thrombin. Most importantly, however, no cross-reactivity to
human factor Va was demonstrated in animals immunized with
salmon thrombin. This result shows that salmon ﬁbrin glue does not
induce immune reactions that might be cross-reactive with human
factor Va, which is the most problematic immunological cross-
reactivity associated with the use of bovine ﬁbrin glue [69]. Also,
peripheral blood C-reactive protein levels were similar in experi-
mental and control rats on the day following the second salmon ﬁbrin
glue challenge (Laidmäe et al., unpublished). These results show that
there is no immediate inﬂammatory reaction in response to salmon
ﬁbrin glue application. The absence of antibody cross-reactivity
between salmon and mammalian proteins is likely due to differences
in glycosylation and other posttranslational modiﬁcations which are
substantially different between ﬁsh and mammals.
1.3. Performance of salmon ﬁbrin in hemostasis and neuronal
wound healing
Salmon ﬁbrin has been tested in animal models of both hemostasis
and neuronal wound healing. In two models of bleeding, puriﬁedof different concentrations correponding to elastic modul of 1800 Pa, 575 Pa, 300 Pa and
cytes for GFAP (green). Adapted from [10].
Fig. 3. Rat cortical neurons embedded in salmon, bovine or human ﬁbrin for 3 days were
immunostained with TuJ1 or Map5/Map1b antibodies to visualize neurites. Scale bar is
50 µm. The effect of the different matrices on neurite growth was quantiﬁed by
measuring the total neurite length per cell (⁎⁎pb0.001 salmon ﬁbrin vs. bovine or
human ﬁbrin). Adapted from [33].
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commercial preparations of human proteins. Salmon ﬁbrin dressing
efﬁciently stopped bleeding in a rat hip penetrating injury model [70]
and bandages lined with lyophilized salmon ﬁbrinogen and thrombin
controls arterial bleeding in a swine model where a 4.4 mm hole was
surgically formed in the aorta [71]. Gels made from salmon ﬁbrinwere
superior to human ﬁbrin gels in supporting the growth and
tubulogenesis of human umbilical vein endothelial cells in vitro [72].
In addition to its utility in hemostasis and formation of a matrix in
which angiogenesis can initiate, ﬁbrin also has advantages for repair of
central and peripheral nervous system injuries in part because of its
mechanical properties, which can be tuned by varying ﬁbrinogen and
thrombin concentrations. Neurons, unlike other cell types, appear to
grow best on very soft materials [11,12] and ﬁbrin ﬁbers are among the
softest biopolymers [73–75]. One consequence of the mechanical
preference of neurons is evident in Fig. 2, which shows how the
relative amounts of neurons and astrocytes grown from a whole
cortical mouse brain preparation are altered as the elastic modulus of
the salmon ﬁbrin gel is changed from1800 Pa to 74 Pa. The softest gels,
which simulate the softness of normal brain [1,3] strongly promotegrowth of neurons and astrocytes, whereas stiffer gels promote
astrocyte adhesion and spreading but not neuronal extension.
Formation of a soft-cell-compatible matrix is accomplished by
ﬁbrin from any source, but the suitability of this matrix for speciﬁc
applications depends on many factors such as the stability of the
matrix to degradative enzymes released at the site of injury and the
multiple signals than can be elicited by sites within the protein
ﬁlaments. For the long-term cultures needed to produce robust
neurite outgrowth with minimal activation of inﬂammation, salmon
ﬁbrin is more effective than human or bovine thrombin to support
neuronal growth in vitro [33]. In part this is because salmon ﬁbrin is
more resistant to rapid degradation in a neuronal setting, and in part
perhaps because of beneﬁcial differences in post-translational
modiﬁcations or primary structure. Fig. 3 shows the greater extension
and more robust growth of neurites from rat brain cortices in salmon
ﬁbrin compared to human or bovine ﬁbrin. Whereas the mechanisms
that account for the greater growth of mammalian neurons in salmon
ﬁbrin are not known, preliminary studies in a rat spinal cord injury
model are consistent with these in vitro ﬁndings.
2. Conclusion
Fibrin gels, characterized by a largemesh size, a low elastic modulus,
and binding sites for integrins and other cellular targets are well suited
to use in neuronal and other tissue engineering contexts. The
effectiveness of ﬁbrin gels in vivo cannot be inferred from its efﬁcacy
in vitro without consideration of its stability at wound sites and the
immunologic response of the host to this foreign material. For proteins
derived from blood or even from recombinant sources possible adverse
effects from infectious agents or bacterial endotoxins are also an
important consideration. Such issues have motivated studies of ﬁbrin
derived from non-mammalian source such as farmed salmon, and
structural differences between salmonandmammalianﬁbrinmight also
contribute to its advantageous use in neural cell growth and repair.
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